Efficacy safety short-term intravenous infusion dopexamine patients severe congestive heart failure randomized double-blind parallel placebo-controlled multicenter study Dopexamine hydrochloride new synthetic catechol unique profile adrenergic dopaminergic activity multicenter parallel design placebo-controlled study patients functional class III IV chronic congestive heart failure placebo infusion different doses dopexamine dose titration sequence patients constant dose infusion period dopexamine rates micrograms/kg body min low intermediate high dose groups patients high dose infusion dopexamine increase cardiac index decrease systemic vascular resistance increase heart rate placebo variables trend NS moderate increase cardiac index low intermediate doses patients dopexamine right atrial systemic arterial pulmonary artery pulmonary capillary wedge pressures minimal change baseline placebo response patients adverse reactions patients high dose patients intermediate dose dopexamine dose reduction hemodynamic variables arbitrary safety limits patients symptoms study medication dopexamine doses cardiac index association reduction systemic vascular resistance Additional clinical studies merits dopexamine comparison inotropic vasodilator medications 